|
| |
Image Results
Loading...
Loading...
ELOXATIN Pages on BioPortfolio:
|
Cytotoxics remain standard bearers
As a result, Datamonitor expects sales of Taxotere, Eloxatin and Gemzar to drop 21%, 7% and 18% annually between 2010 and 2014 respectively, ...
http://www.bioportfolio.com/news/datamonitor_145.htm...
|
BioPortfolio's Approved Drugs News by Tradename - E
ELOXATIN ...
http://www.bioportfolio.co.uk/approved_drugs/approved_drug_n...
|
BioPortfolio Limited Cancer Market Trends 2008 - 2012
Eloxatin (oxaliplatin). Chapter 5 Key companies. Major cancer players. Leading companies ... Figure 47: Eloxatin (oxaliplatin) forecast sales, 2003-2012 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_592.html...
|
BioPortfolio Limited Oncology Market Leaders - Analyses and ...
Table 3.14 Eloxatin Market Sales Forecast, 2008-2023. Table 3.15 Global Sales of Arimidex, 2004-2007 .... Figure 3.13 Global Sales of Eloxatin, 2004-2007 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_468.html...
|
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming ...
This is in part, driven by the sales of Eloxatin (oxaliplatin; Sanofi-Aventis) and Camptosar. However, by 2017, the antimetabolite brands class are set to ...
http://www.bioportfolio.com/cgi-bin/acatalog/Commercial_Insi...
|
Colorectal Cancer Drug Pipeline Update 2008
Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as ...
http://www.bioportfolio.com/cgi-bin/acatalog/Colorectal_Canc...
|
BioPortfolio News: Hospira, Inc. - Hospira Launches Generic ...
The medication is a generic version of Sanofi-Aventis' Eloxatin(R), which posted 2008 U.S. sales of approximately $1.4 billion. ...
http://www.bioportfolio.com/news/Hospira_Launches_Generic_Ox...
| Results from other life science and pharmaceutical sites:
Oxaliplatin - Wikipedia, the free encyclopedia
24 Aug 2009 ... Eloxatin gained European approval in 1996 (firstly in France) and ... Eloxatin is covered by patent numbers 5338874 (Expiry Apr 07,2013), ...
http://en.wikipedia.org/wiki/Oxaliplatin...
|
Eloxatin Information
18 Jun 2009 ... On January 9, 2004, the Food and Drug Administration announced the approval of Eloxatin (oxaliplatin) injection for the initial treatment of ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...
|
eloxatin (oxaliplatin) solution, concentrate [sanofi-aventis US ...
ELOXATIN (oxaliplatin injection) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic ...
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7135...
|
Questions and Answers about Eloxatin (oxaliplatin for injection)
1 Jul 2009 ... Eloxatin is a platinum-based anticancer drug. It is the platinum that destroys the cancer cells. The active ingredient in Eloxatin is ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...
|
eloxatin (oxaliplatin) powder, for solution for intravenous use ...
These highlights do not include all the information needed to use eloxatin safely and effectively. See full prescribing information for eloxatin. ...
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5664...
|
Oxaliplatin (Eloxatin)
In January 2004, the FDA approved Eloxatin (oxaliplatin for injection) in combination with 5-FU/LV for the first-line treatment of advanced colorectal ...
http://www.aetna.com/cpb/medical/data/600_699/0683.html...
|
Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant ...
Oxaliplatin (Eloxatin®, Sanofi-Synthelabo S.p.A, Milan, Italy), a third- generation platinum analogue, is a diaminocyclohexane platinum that forms ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361378/...
|
International Approvals: Januvia, Synvisc-One, Eloxatin
29 Jan 2008 ... Europe has approved 2 new indications for sitagliptin tablets (Januvia) and a new formulation of hylan GF 20 (Synvisc-One); ...
http://www.medscape.com/viewarticle/569376...
|
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant ...
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, ...
http://www.ncbi.nlm.nih.gov/pubmed/16508631...
|
FDA Approvals: Eloxatin, Orphan Drugs for Leukemia and Renal Cell ...
The FDA has approved expanded indications for oxaliplatin (Eloxatin), orphan drug status for cloretazine (VNP40101M) and BAY 43-9006, a breathing device ...
http://www.medscape.com/viewarticle/494155...
|
|
